Synaptogenix | Neurotrope BioScience to Present at the Oppenheimer 27th Annual Healthcare Conference
post-template-default,single,single-post,postid-22605,single-format-standard,ajax_fade,page_not_loaded,,select-theme-ver-4.4,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Neurotrope BioScience to Present at the Oppenheimer 27th Annual Healthcare Conference


NEW YORK, March 16, 2017  PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, including Alzheimer’s disease, today announced that it is scheduled to present at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017 at 10:20 a.m. Eastern Time at the Westin New York Grand Central Hotel in New York, New York. Neurotrope’s lead compound, bryostatin-1, has demonstrated, in extensive pre-clinical studies and early clinical observations, a unique potential for multi-modal efficacy to restore degenerated synaptic networks, prevent neuronal death, and reverse cognitive deficits, while also potentially preventing the pathologic hallmarks of Alzheimer’s dementia, amyloid plaques and neurofibrillary tangles.


Susanne Wilke, PhD, Chief Executive Officer of Neurotrope BioScience and Dr. Daniel Alkon, President and Chief Scientific Officer, will be presenting at the conference.


A simultaneous live audio webcast is also available at:


A webcast replay will be available afterwards via the Company’s website at under the Investors section.


Company executives will also be available for one on one meetings with investors on March 21st and 22nd.



About Neurotrope



Neurotrope is at the forefront of developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer’s dementia and other neurodegenerative diseases. The Company’s world-class science is a paradigm shifting approach that treats some of the underlying causes of Alzheimer’s disease.


The scientific basis of our treatment is activation of Protein Kinase C isozymes ε and α by bryostatin-1, a natural product, which in mouse Alzheimer’s disease models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer’s dementia.


Neurotrope is conducting a Phase 2 trial of bryostatin-1 in the treatment of moderate to severe Alzheimer’s dementia, as well as preclinical studies of bryostatin-1 as a treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Syndrome, three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for bryostatin-1 as a treatment for Fragile X Syndrome. Bryostatin-1 has undergone testing in over 1,500 people establishing a large safety database.


Forward-Looking Statements


Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the proposed study and timing and outcome of such study, and continued development of use of bryostatin-1 for Alzheimer’s dementia and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s clinical development of bryostatin-1, the potential timing and outcomes of the Company’s clinical studies of bryostatin-1, the Company’s inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company’s patent portfolio, and reliance on the license agreement with Cognitive Research Enterprises, Inc., the Company’s inability to expand the Company’s business, the Company’s inability to meet listing requirements for major stock exchanges, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company’s raw materials, existing or increased competition, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. The Company does not undertake to update these forward-looking statements.



Please visit for further information.


For additional information, please contact:

Neurotrope BioScience, Inc.
Jeffrey Benison, Director of Corporate Communications
212.334.8709 or 516.286.6099